Objective: 1.5T Dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) parameters combined with serum chemokine ligand18 (CC-chemokine Ligand18) were analyzed. The diagnostic value of CCL18 in ovarian cancer. Methods: The clinical data of 76 patients with ovarian cancer admitted to our hospital from April 2021 to July 2023 were retrospectively collected as the study group, and the clinical data of 76 patients with benign tumors were selected as the control group according to a 1:1 ratio. Patients in the study group were divided into stage I (30 cases), stage II (21 cases), stage III (14 cases) and stage IV (11 cases) according to different stages. DCE-MRI parameters and serum CCL-18 levels were analyzed and compared between the two groups at admission. The correlation between their levels and ovarian cancer was analyzed by partial regression. The diagnostic value of combined detection for ovarian cancer in patients with different stages was analyzed by comparing the level of each index at admission. Result: The Volume transfer constant (Ktrans) and Rate constant (Rate constant) were calculated when the study group was admitted to hospital. Extravascular extracellular volume fraction (Kep) and serum CCL-18 levels were significantly higher than those in control group (P < 0.05). Logistic regression analysis showed that high levels of parameters Ktrans, Kep, Ve and serum CCL-18 at admission were risk factors for ovarian cancer (P < 0.05). DCE-MRI parameters and serum CCL-18 levels were compared in different stages at admission, patients with stage Ⅰ < stage Ⅱ < stage Ⅲ < stage Ⅳ (P < 0.05). the Area under the curve (AUC) of Ktrans, Kep, Ve and serum CCL-18 in the diagnosis of ovarian cancer at admission was 0.754, which was higher than that detected by each index alone (P < 0.05). Conclusion: DCE-MRI parameters and serum CCL-18 levels are related to the occurrence and development of ovarian cancer, and clinical combined detection can improve the clinical diagnosis efficiency of ovarian cancer.